{"nctId":"NCT03359811","briefTitle":"Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway","startDateStruct":{"date":"2017-11-27","type":"ACTUAL"},"conditions":["Peritoneal Cancer"],"count":75,"armGroups":[{"label":"Standard-of-Care Thoracic Epidural Analgesia (TEA)","type":"EXPERIMENTAL","interventionNames":["Drug: Local Anesthetic Solution"]},{"label":"4Q-TAP Blocks","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bupivacaine HCl","Drug: Liposomal Bupivacaine"]}],"interventions":[{"name":"Local Anesthetic Solution","otherNames":[]},{"name":"Bupivacaine HCl","otherNames":[]},{"name":"Liposomal Bupivacaine","otherNames":["EXPAREL"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Written Informed consent\n2. 18 years old or older\n3. American Society of Anesthesiologists physical status (ASA) 1-3\n4. Scheduled surgery: open elective CRS-HIPEC\n5. Able to complete the QoR 15 questionnaire\n6. Patients scheduled to receive intraoperative chemotherapy\n\nExclusion Criteria:\n\n1. Thrombocytopenia (platelet count: \\<100,000 cell/dL), coagulopathy (International Normalized Ratio \\> 1.5, PT\\>16.5 seconds or aPTT \\> 35.9 seconds)\n2. Bupivacaine or liposomal bupivacaine sensitive or known allergy;\n3. Pregnancy or breastfeeding patients\n4. Patients with recent (within 60 days preoperatively) history severe hepatic disease (defined as liver injury with encephalopathy plus impaired synthetic liver function (i.e. \\>1.5)\n5. Patients with recent (within 15 days preoperatively) history deteriorate kidney function (creatinine serum concentrations \\> 2.5 mg/dL or eGFR \\< 30 mL/kg/min)\n6. Chronic opioid use defined as daily opioid use for more than one month prior the scheduled date of surgery","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Efficacy of TEA vs 4Q-TAP in QoR at Postoperative Day (POD)2","description":"To compare the efficacy of 4 quadrants TAP blocks (4Q-TAP) versus Thoracic Epidural Analgesia (routine care) on the quality of recovery 48 hours after CRS-HIPEC surgery, measure by QoR-15 changes from Pre-Op to POD2. The QoR scale is a validated scoring system that allows for the quantification of a patient's early postoperative health status. The minimum score 0 and maximum score 150. The higher score mean a better outcome.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-45","spread":null},{"groupId":"OG001","value":"-50","spread":null}]}]}]},{"type":"SECONDARY","title":"4Q-TAP Versus TEA on Postoperative Pain","description":"Pain intensity at rest and cough measure using a Validity and Reliability of the Verbal Numerical Rating Scale (VNRS) (0 = no pain - 10 = worst pain ever). Higher numerical scores on the scale indicate more pain, thus a worse outcome. Data reported as time-weighted pain scores from discharge from the PACU until 48 hours after the end of surgery.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of the Total Opioid Consumption Between Patients With 4Q-TAP Versus TEA","description":"Opioid Consumption reported as morphine equivalents required during the 48 hours after the end of surgery.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Comparison of the Length of Stay (LOS) Between Patients With 4Q-TAP Versus TEA","description":"Length of stay calculated from day of surgery to date of hospital discharge.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events Related to 4Q-TAP Versus TEA","description":"An adverse event is any symptom, sign, illness, or experience which develops or worsens during the course of the study, whether or not the event is considered related to study drug. Adverse events (AEs) related to the study interventions recorded within the first 48 hours after the end of surgery.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Incidence of Opioid-Related Adverse Events Related to 4Q-TAP Versus TEA 48","description":"Opioid-related adverse (i.e. respiratory depression, pruritus, sedation, delirium) within the first 48 hours after the end of surgery.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Incidence of Postoperative Complications and Morbidity in Patients Receiving 4Q-TAP Versus TEA","description":"Postoperative complications recorded using Clavien-Dindo scale and POMS.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":33},"commonTop":["Nausea","Hypotension","Dry mouth","Pruritus","Low urinary input"]}}}